English | 简体中文 | LP ACCESS

About artrix

This author has not yet filled in any details.
So far artrix has created 60 blog entries.

Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)2021-11-27T10:44:56-08:00

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders2021-08-28T22:50:11-07:00

Palo Alto
Global Headquarters

Beijing
 

Shanghai 
 

Taipei  
 

Hong Kong   
 

Email: info@vivocapital.com
Vivo Capital®, SEC registered, effective 6/19/2014. All rights reserved.
Go to Top